OrganaBio is a new Miami-based manufacturer specializing in stem cell and gene-modified cell therapies. There is a tremendous potential for both autologous and allogeneic mesenchymal stem cell therapies and exosomes, and OrganaBio is focused on complete product development and manufacturing of these therapies. This includes everything from tissue collection to cell processing and delivery. Cancer immunotherapies will require the highest level of cGMP and OrganaBio’s ability to fully process patient tissues in a locally-based, but world-class lab, removes the need for costly (and potentially tissue-damaging) process of freezing, thawing, and shipping tissues. OrganaBio was founded in 2018 by a mix of cell therapy scientists and experienced business people and has equity capital commitments in excess of $20 million.